Form 4: InMed Pharmaceuticals Director Nicole Lemerond Acquires Stock Options

Director Nicole Lemerond of InMed Pharmaceuticals Inc. was granted 550 stock options on December 20, 2024, which will vest on December 19, 2025, or immediately prior to the next Annual General Meeting.

Summary

• Nicole Lemerond, a director at InMed Pharmaceuticals Inc., was granted 550 employee stock options on December 20, 2024.
• These options have an exercise price of $4.14 per share.
• The options will vest 100% on the one-year anniversary of the grant date, December 19, 2025, or immediately prior to the next Annual General Meeting, whichever is sooner.
• The underlying securities for these options are 550 common shares.
• The report also notes that InMed Pharmaceuticals underwent a 1-for-20 reverse stock split on November 14, 2024.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction of stock options to a director, which is generally viewed as a neutral to slightly positive event as it aligns interests. There is no indication of any negative or concerning information.

Positives

• The granting of stock options to a director aligns their interests with the company's performance and shareholder value.

Industry Context

Stock option grants to directors are a common practice in publicly traded companies to incentivize performance and align interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for directors in publicly traded companies, similar to practices at companies like Canopy Growth and Aurora Cannabis in the cannabis sector.
• The vesting period of one year is also typical, aligning with common industry practices for equity-based compensation.

Stakeholder Impact

• The stock option grant may have a minor positive impact on shareholder sentiment as it aligns director interests with company performance.

Key Dates

Keywords

stock options, insider trading, director, InMed Pharmaceuticals, equity, reverse stock split, vesting